Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Predictive Oncology stock price, quote, forecast and news

POAI
US74039M2008
A2PUKH

Price

0.79
Today +/-
+0.03
Today %
+3.68 %
P

Predictive Oncology stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Predictive Oncology stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Predictive Oncology stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Predictive Oncology stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Predictive Oncology's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Predictive Oncology Stock Price History

DatePredictive Oncology Price
9/27/20240.79 undefined
9/26/20240.76 undefined
9/25/20240.79 undefined
9/24/20240.80 undefined
9/23/20240.82 undefined
9/20/20240.82 undefined
9/19/20240.88 undefined
9/18/20240.88 undefined
9/17/20240.92 undefined
9/16/20240.90 undefined
9/13/20240.90 undefined
9/12/20240.88 undefined
9/11/20240.95 undefined
9/10/20240.95 undefined
9/9/20240.95 undefined
9/6/20240.92 undefined
9/5/20240.91 undefined
9/4/20240.92 undefined
9/3/20240.93 undefined

Predictive Oncology Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Predictive Oncology, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Predictive Oncology from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Predictive Oncology’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Predictive Oncology. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Predictive Oncology’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Predictive Oncology’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Predictive Oncology’s growth potential.

Predictive Oncology Revenue, EBIT and net profit per share

DatePredictive Oncology RevenuePredictive Oncology EBITPredictive Oncology Net Income
2026e15.76 M undefined0 undefined340,170 undefined
2025e9.52 M undefined-2.34 M undefined-1.09 M undefined
2024e1.58 M undefined-1.37 M undefined-13.81 M undefined
20231.78 M undefined-13.92 M undefined-13.98 M undefined
20221.51 M undefined-15.26 M undefined-25.74 M undefined
20211.42 M undefined-13.47 M undefined-19.66 M undefined
20201.25 M undefined-12.49 M undefined-26.44 M undefined
20191.41 M undefined-13.78 M undefined-19.68 M undefined
20181.41 M undefined-7.86 M undefined-10.09 M undefined
2017650,000 undefined-6.05 M undefined-6 M undefined
2016460,000 undefined-6.53 M undefined-6.53 M undefined
2015650,000 undefined-4.4 M undefined-4.79 M undefined
2014950,000 undefined-6.46 M undefined-6.83 M undefined
2013470,000 undefined-8.93 M undefined-9.41 M undefined
2012190,000 undefined-7.16 M undefined-7.42 M undefined
2011100,000 undefined-4.11 M undefined-4.49 M undefined
20100 undefined-2.35 M undefined-1.35 M undefined
200920,000 undefined-2.44 M undefined-2.89 M undefined
20080 undefined-1.67 M undefined-1.76 M undefined

Predictive Oncology Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (k)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
00000000001111111915
-----------------800.0066.67
----------100.00---100.00100.00---
00000000001,0000001,0001,000000
-1-2-2-4-7-8-6-4-6-6-7-13-12-13-15-13-1-20
-----------700.00-1,300.00-1,200.00-1,300.00-1,500.00-1,300.00-100.00-22.22-
-1-2-1-4-7-9-6-4-6-6-10-19-26-19-25-13-13-10
-100.00-50.00300.0075.0028.57-33.33-33.3350.00-66.6790.0036.84-26.9231.58-48.00--92.31-
000000000.010.030.060.140.62.743.654.01000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Predictive Oncology Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Predictive Oncology is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (k)INVENTORIES (k)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2008200920102011201220132014201520162017201820192020202120222023
                               
0.460.020.010.120.010.10.024.862.151.010.160.150.6828.222.078.73
02005040100604040140230300260350330333.7
00000000067050000000
000100150120370230270270240190290390430494.37
17010010303060190270150290320160290510530521.7
0.630.140.020.30.230.380.645.42.612.381.450.81.5229.4523.3610.08
0.010.010.01000.160.20.140.10.090.182.245.223.332.053.96
0000000000000000
0000000001.071.1100000
0.140.140.140.140.140.050.070.090.10.10.963.653.43.960.250.25
0000000000015.692.816.8600
00000000000012017080124.1
0.150.150.150.140.140.210.270.230.21.262.2521.5811.5514.322.384.34
0.780.290.170.440.370.590.915.632.813.643.722.3813.0743.7725.7414.42
                               
0.080.110.140.321.042.20.030.070.050.080.140.080.20.660.790.04
2.753.575.058.8414.9523.2830.0944.5347.8957.3863.0293.65110.83167.65174.76175.99
-3.14-6.03-7.38-11.87-19.29-28.7-35.64-40.49-47.02-54.77-63.11-82.5-108.38-128.04-153.78-167.76
0000000000000000
0000000000000000
-0.31-2.35-2.19-2.71-3.3-3.22-5.524.110.922.690.0511.232.6540.2721.778.27
0.50.810.770.730.731.062.190.650.220.140.453.161.371.020.941.34
0.310.20.50.571.62.063.070.861.350.791.282.833.191.92.322.15
0360000701010101030090350320620309.47
000000.280.940001.634.80000.15
0.20.060.071.061.0800000004.43000
1.011.431.342.363.413.476.211.521.580.943.6610.889.343.243.883.95
0.10.131.010.630.0900000000000
0000000000000000
01.070.010.170.170.340.2100.31000.271.080.270.092.19
0.11.21.020.80.260.340.2100.31000.271.080.270.092.19
1.112.632.363.163.673.816.421.521.890.943.6611.1510.423.513.976.15
0.80.280.170.450.370.590.95.632.813.633.7122.3813.0743.7825.7414.42
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Predictive Oncology provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Predictive Oncology's financial health and stability.

Assets

Predictive Oncology's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Predictive Oncology must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Predictive Oncology after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Predictive Oncology's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200820092010201120122013201420152016201720182019202020212022
-1-2-1-4-7-9-6-4-6-6-10-19-25-19-25
0000000000001,0001,0001,000
000000000000000
0000112-30-101-1-10
01024411123813711
000000000000000
000000000000000
0-10-1-1-3-3-7-4-4-5-8-12-12-12
000000000000000
000000000-1-100-100
000000000-1000-90
000000000000000
000001100021100
100102213153711556
100114312155912506
--------------5.00-
000000000000000
00000004-3-100027-6
-0.94-1.31-0.82-1.78-1.18-4.08-3.49-7.55-4.42-4.52-5.52-8.76-12.62-13.17-12.85
000000000000000

Predictive Oncology stock margins

The Predictive Oncology margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Predictive Oncology. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Predictive Oncology.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Predictive Oncology's sales revenue. A higher gross margin percentage indicates that the Predictive Oncology retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Predictive Oncology's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Predictive Oncology's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Predictive Oncology's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Predictive Oncology. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Predictive Oncology's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Predictive Oncology Margin History

Predictive Oncology Gross marginPredictive Oncology Profit marginPredictive Oncology EBIT marginPredictive Oncology Profit margin
2026e64.34 %0 %2.16 %
2025e64.34 %-24.58 %-11.43 %
2024e64.34 %-86.65 %-874.66 %
202364.34 %-782.06 %-785.58 %
202266.23 %-1,010.6 %-1,704.64 %
202165.49 %-948.59 %-1,384.51 %
202064.8 %-999.2 %-2,115.2 %
201962.41 %-977.3 %-1,395.74 %
201870.92 %-557.45 %-715.6 %
201778.46 %-930.77 %-923.08 %
201658.7 %-1,419.57 %-1,419.57 %
201553.85 %-676.92 %-736.92 %
201460 %-680 %-718.95 %
201359.57 %-1,900 %-2,002.13 %
201231.58 %-3,768.42 %-3,905.26 %
201140 %-4,110 %-4,490 %
201064.34 %0 %0 %
200950 %-12,200 %-14,450 %
200864.34 %0 %0 %

Predictive Oncology Stock Sales Revenue, EBIT, Earnings per Share

The Predictive Oncology earnings per share therefore indicates how much revenue Predictive Oncology has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Predictive Oncology earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Predictive Oncology's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Predictive Oncology’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Predictive Oncology's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Predictive Oncology Revenue, EBIT and net profit per share

DatePredictive Oncology Sales per SharePredictive Oncology EBIT per sharePredictive Oncology Earnings per Share
2026e2.36 undefined0 undefined0.05 undefined
2025e1.43 undefined0 undefined-0.16 undefined
2024e0.24 undefined0 undefined-2.07 undefined
20230.44 undefined-3.47 undefined-3.48 undefined
20220.41 undefined-4.18 undefined-7.05 undefined
20210.52 undefined-4.92 undefined-7.18 undefined
20202.08 undefined-20.82 undefined-44.07 undefined
201910.07 undefined-98.43 undefined-140.57 undefined
201823.5 undefined-131 undefined-168.17 undefined
201721.67 undefined-201.67 undefined-200 undefined
201646 undefined-653 undefined-653 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined

Predictive Oncology business model

Predictive Oncology Inc is an emerging company in the field of cancer research and treatment. It was founded in 2002 under the name Precision Therapeutics and has since focused on developing new diagnostic and therapeutic procedures for cancer. The business model of Predictive Oncology is based on collaboration with pharmaceutical companies and research institutions to develop new technologies and products for cancer therapy. The focus is on personalized medicine, which enables treatment options tailored to individual patient needs. The company is divided into several divisions, each covering different areas of cancer research. These include predictive medicine, pharmacy, and diagnostics. Predictive Oncology has developed several products that can be used in predictive medicine. This includes the OncoTect iOCT System, which allows prediction of the effectiveness of chemotherapy for a specific type of cancer. Based on genetic analysis, the system can determine before treatment whether the drug used for chemotherapy is actually effective or if another drug may be more suitable. Another important product of Predictive Oncology is the Skyline Ventures Test Kit, which is used in pharmacy. The kit allows pharmaceutical companies to test the potential effect of a new drug on specific cancer cells before testing it on patients in clinical trials. By pre-testing the effectiveness, unnecessary studies can be avoided and the development of new drugs can be accelerated. In the field of diagnostics, Predictive Oncology has developed the Cchek system, which enables early detection of certain types of cancer through RNA analysis. The system can provide indications of the development of a tumor at an early stage, enabling early treatment. One of the recent developments of Predictive Oncology is the acquisition of Soluble Therapeutics Inc, which specializes in protein analysis. Through the acquisition, Predictive Oncology hopes to further increase its capacities in personalized cancer treatment. Overall, Predictive Oncology is one of the leading companies in the field of cancer research. Through a consistent focus on personalized medicine and close collaboration with research institutions and pharmaceutical companies, the company has already produced some promising developments. In the future, it is expected that Predictive Oncology will bring further innovative products and technologies to the market to treat cancer patients more effectively. Predictive Oncology is one of the most popular companies on Eulerpool.com.

Predictive Oncology SWOT Analysis

Strengths

Predictive Oncology Inc has several strengths that contribute to its competitive edge in the market. One of its key strengths is its expertise and experience in the field of oncology. With a team of highly skilled and knowledgeable professionals, the company has the ability to develop advanced predictive models for cancer treatment and diagnosis.

Another strength of Predictive Oncology Inc is its strong portfolio of intellectual property. The company holds numerous patents and proprietary technology, which gives it a significant advantage over competitors. This portfolio provides a foundation for the development of innovative solutions and enables Predictive Oncology Inc to maintain a strong market position.

Additionally, the company has established strategic partnerships with leading healthcare organizations and research institutions. These collaborations enhance Predictive Oncology Inc's access to clinical data and help drive the validation and adoption of its predictive models. This strong network of partnerships further strengthens the company's position and provides opportunities for growth and expansion.

Weaknesses

Despite its strengths, Predictive Oncology Inc also faces certain weaknesses that could potentially hinder its growth. One of these weaknesses is its dependency on external funding. As a research-intensive company, Predictive Oncology Inc requires significant financial resources to support its operations and research activities. Any disruptions in funding could impact the company's ability to execute its strategic plans effectively.

Another weakness is the complexity and lengthy development cycle of predictive models in the field of oncology. Developing accurate and reliable predictive models requires extensive research and validation, which can be time-consuming and resource-intensive. This may result in delays in bringing new products or services to market, potentially giving competitors an advantage.

Opportunities

Predictive Oncology Inc operates in an industry that is constantly evolving and presents several opportunities. One of the key opportunities is the increasing demand for personalized medicine in oncology. With advancements in genomics and molecular diagnostics, there is a growing need for predictive models that can tailor treatment plans to individual patients. Predictive Oncology Inc is well-positioned to capitalize on this trend and offer customized solutions to healthcare providers.

The company also has the opportunity to expand its market presence globally. With its strong intellectual property portfolio and strategic partnerships, Predictive Oncology Inc has the potential to enter new markets and establish collaborations with international healthcare organizations. This would not only diversify its revenue streams but also enhance its reputation as a global leader in predictive oncology.

Threats

Predictive Oncology Inc operates in a highly competitive market, which poses a threat to its market share and profitability. Competitors, including established companies and emerging startups, may develop similar predictive models or technologies that could rival those offered by Predictive Oncology Inc. Therefore, maintaining a competitive edge and continuously innovating will be crucial for the company's long-term success.

Another potential threat is the regulatory environment in the healthcare industry. Compliance with stringent regulations and obtaining necessary approvals for new products and services can be challenging and time-consuming. Changes in regulations or the introduction of new regulatory requirements could impact the company's ability to bring its products to market or limit its ability to operate in certain regions.

Predictive Oncology Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Predictive Oncology historical P/E ratio, EBIT, and P/S ratio.

Predictive Oncology shares outstanding

The number of shares was Predictive Oncology in 2023 — This indicates how many shares 4.015 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Predictive Oncology earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Predictive Oncology's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Predictive Oncology’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Predictive Oncology's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Predictive Oncology Stock splits

In Predictive Oncology's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Predictive Oncology.

Predictive Oncology latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/2022-0.82 -1  (-22.55 %)2022 Q1
12/31/2021-0.03 -0.13  (-409.8 %)2021 Q4
9/30/2021-0.05 -0.08  (-56.86 %)2021 Q3
6/30/2021-0.08 -0.05  (34.64 %)2021 Q2
3/31/2021-0.09 -0.11  (-19.83 %)2021 Q1
12/31/2020-0.18 -0.7  (-281.26 %)2020 Q4
1

Predictive Oncology list of shareholders

%
Name
Stocks
Change
Date
2.10801 % The Vanguard Group, Inc.140,604012/31/2023
1.81105 % Raymond James & Associates, Inc.120,7972,56812/31/2023
0.56180 % Geode Capital Management, L.L.C.37,472012/31/2023
0.44837 % Nuzum (Charles Lee Sr)29,9063,2684/5/2024
0.31787 % St Clair (Gregory Sr)21,2023,2684/5/2024
0.31237 % RB Capital Management, LLC20,835012/31/2023
0.31237 % Engle (J Melville)20,8352,41411/14/2023
0.28955 % Chung-Welch (Nancy)19,3132,3534/5/2024
0.25514 % Handley (Daniel E)17,0182,3534/5/2024
0.25243 % State Street Global Advisors (US)16,837012/31/2023
1
2
3
4
5
...
6

Predictive Oncology Executives and Management Board

Mr. Raymond Vennare71
Predictive Oncology Chairman of the Board, Chief Executive Officer (since 2021)
Compensation 201,078
Mr. Chuck Nuzum75
Predictive Oncology Lead Independent Director
Compensation 140,562
Dr. Nancy Chung-Welch63
Predictive Oncology Independent Director
Compensation 118,339
Mr. Gregory St. Clair57
Predictive Oncology Independent Director
Compensation 85,003
Dr. Daniel Handley63
Predictive Oncology Independent Director
Compensation 73,892
1
2

Predictive Oncology Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Interpace Biosciences Stock
Interpace Biosciences
SupplierCustomer0,280,700,790,590,780,33
1

Most common questions regarding Predictive Oncology

What values and corporate philosophy does Predictive Oncology represent?

Predictive Oncology Inc represents values of innovation, precision, and expertise in the field of oncology. The company is dedicated to leveraging advanced technologies and data-driven analytics to develop personalized cancer therapies. With a focus on predictive modeling, Predictive Oncology aims to revolutionize cancer treatment by improving patient outcomes and reducing healthcare costs. Committed to staying at the forefront of scientific advancements, the company collaborates with leading institutions and experts in oncology research. By combining cutting-edge technology with deep domain knowledge, Predictive Oncology strives to empower healthcare providers and patients with tailored solutions for effective cancer management.

In which countries and regions is Predictive Oncology primarily present?

Predictive Oncology Inc is primarily present in the United States with its headquarters located in Minneapolis, Minnesota. As a leading precision medicine company, Predictive Oncology focuses on developing innovative solutions to improve cancer care and treatment.

What significant milestones has the company Predictive Oncology achieved?

Predictive Oncology Inc has achieved several significant milestones in the field of oncology. These include the development of innovative technology solutions for cancer research and personalized medicine. The company has successfully built a proprietary database with extensive molecular and clinical information, facilitating the discovery of key insights into cancer biology. Furthermore, Predictive Oncology has established strategic collaborations with leading research institutions and pharmaceutical companies to accelerate the development and validation of its novel approaches. The company's commitment to advancing precision medicine has resulted in notable achievements and recognition within the industry. Predictive Oncology Inc continues to strive towards improving patient outcomes and revolutionizing cancer treatment through cutting-edge discoveries and partnerships.

What is the history and background of the company Predictive Oncology?

Predictive Oncology Inc, a leading healthcare company, has a rich history and remarkable background. With a focus on revolutionizing cancer treatment, the company operates through its subsidiaries to develop cutting-edge therapies and personalized medicine. Originally founded in 2002 as Precision Therapeutics, Predictive Oncology has since evolved to incorporate advanced data analytics and artificial intelligence to improve oncology outcomes. This innovative approach aims to identify effective drug combinations and provide insights into individual patient response, ultimately saving lives. Through its commitment to developing breakthrough solutions, Predictive Oncology Inc has emerged as a trailblazer in the field of oncology, continuously striving for advancements and better patient care.

Who are the main competitors of Predictive Oncology in the market?

The main competitors of Predictive Oncology Inc in the market include companies like Guardant Health Inc, Foundation Medicine Inc, and Tempus Labs.

In which industries is Predictive Oncology primarily active?

Predictive Oncology Inc is primarily active in the healthcare and biotechnology industries.

What is the business model of Predictive Oncology?

Predictive Oncology Inc is a company with a business model focused on providing predictive and personalized medicine solutions for cancer patients. Their main goal is to use advanced technology and data analytics to improve the outcome of cancer treatments. Predictive Oncology Inc incorporates artificial intelligence, machine learning, and biomarker discovery to identify and develop effective treatment strategies. By analyzing molecular and genetic information, the company aims to assist physicians in making informed decisions and providing patients with personalized therapies. Through their innovative approach, Predictive Oncology Inc aims to revolutionize cancer care and contribute to better patient outcomes.

What is the P/E ratio of Predictive Oncology 2024?

The Predictive Oncology P/E ratio is -0.23.

What is the P/S ratio of Predictive Oncology 2024?

The Predictive Oncology P/S ratio is 2.

What is the AlleAktien quality score of Predictive Oncology?

The AlleAktien quality score for Predictive Oncology is 4/10.

What is the revenue of Predictive Oncology 2024?

The expected Predictive Oncology revenue is 1.58 M USD.

How high is the profit of Predictive Oncology 2024?

The expected Predictive Oncology profit is -13.81 M USD.

What is the business model of Predictive Oncology

Predictive Oncology Inc is a company specializing in the development of predictive models to support personalized medicine in oncology. Its main goal is to offer more precise treatment options for cancer patients and thus improve cure rates. The business model of Predictive Oncology Inc consists of three main areas: (1) Predictive modeling of cancer, (2) services in the field of personalized medicine, and (3) production of medications. The predictive modeling of cancer performed by the company is based on the analysis of large datasets, including genetic, clinical, and molecular data from cancer patients. These data are then used to create predictive models that enhance the understanding of cancer biology and support personalized medicine. Predictive Oncology Inc also offers services in the field of personalized medicine based on the results of predictive modeling of cancer. These services include genetic tests that enable more precise cancer diagnosis, as well as consulting services for doctors to provide more precise treatment options based on the individual needs of the patient. The company also produces medications based on the results of predictive modeling of cancer. By utilizing genetic and molecular information, Predictive Oncology Inc can develop medications specifically tailored to the needs of cancer patients to ensure higher effectiveness and fewer side effects. Overall, Predictive Oncology Inc provides a comprehensive solution to the problem of personalized medicine in oncology. By integrating predictive modeling, personalized services, and the production of specialized medications, the company can offer more precise treatment options tailored to the needs of each individual patient. The customers of Predictive Oncology Inc are doctors, hospitals, and laboratories in need of services in the field of personalized medicine, as well as pharmaceutical companies interested in the development of specialized cancer medications. As a leading company in the field of personalized medicine in oncology, Predictive Oncology Inc has a strong market presence and is well-positioned to benefit from the growing demand for more precise treatment options in cancer medicine. Overall, the business model of Predictive Oncology Inc is a unique combination of predictive modeling, personalized services, and the production of specialized medications. By providing more precise treatment options, the company can contribute to improving cure rates in cancer and prolonging patients' lives.

What is the Predictive Oncology dividend?

Predictive Oncology pays a dividend of 0 USD distributed over payouts per year.

How often does Predictive Oncology pay dividends?

The dividend cannot currently be calculated for Predictive Oncology or the company does not pay out a dividend.

What is the Predictive Oncology ISIN?

The ISIN of Predictive Oncology is US74039M2008.

What is the Predictive Oncology WKN?

The WKN of Predictive Oncology is A2PUKH.

What is the Predictive Oncology ticker?

The ticker of Predictive Oncology is POAI.

How much dividend does Predictive Oncology pay?

Over the past 12 months, Predictive Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Predictive Oncology is expected to pay a dividend of 0 USD.

What is the dividend yield of Predictive Oncology?

The current dividend yield of Predictive Oncology is .

When does Predictive Oncology pay dividends?

Predictive Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Predictive Oncology?

Predictive Oncology paid dividends every year for the past 0 years.

What is the dividend of Predictive Oncology?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Predictive Oncology located?

Predictive Oncology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Predictive Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Predictive Oncology from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Predictive Oncology pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Predictive Oncology in the year 2023?

In the year 2023, Predictive Oncology distributed 0 USD as dividends.

In which currency does Predictive Oncology pay out the dividend?

The dividends of Predictive Oncology are distributed in USD.

All fundamentals about Predictive Oncology

Our stock analysis for Predictive Oncology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Predictive Oncology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.